# Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension

> **NCT00867490** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 186 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Candesartan+HCTZ - Phase 1
- **DRUG:** Aliskiren+HCTZ - Phase 2
- **DRUG:** Aliskiren+HCTZ+amlodipine - Phase 3

## Key facts

- **NCT ID:** NCT00867490
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2011-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00867490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00867490, "Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00867490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*